CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Key Points

• To evaluate the efficacy and toxicity of CAR-T therapy for treating relapsed/refractory large B-cell lymphoma in individuals living with HIV.
• Assessment of CAR-T therapy outcomes in HIV-positive patients
• Evaluation of treatment toxicity levels
• Comparative analysis of efficacy in relapsed/refractory cases
• CAR-T therapy demonstrates significant patient response rates in large B-cell lymphoma
• Toxicity profile reveals manageable side effects
• Considerations for tailored treatment approaches in HIV-positive individuals are emphasized